ArticleCureus2024
Evaluation of the Demographics, Clinical Laboratory Parameters, and Outcomes of Hospitalized Oncological Versus Non-oncological COVID-19 Patients.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction The COVID-19 pandemic emerged globally in 2019, exposing healthcare vulnerabilities. This study delves into the impact of COVID-19 on cancer patients, a high-risk group with increased susceptibility and mortality rates. Recent research underscores cancer patients' vulnerability to severe disease, often due to compromised immunity. Materials and methods This retrospective study analyzed data from 474 adult COVID-19 patients, admitted between March 2020 and July 2023. Patients were categorized into two groups: those with a medically recorded oncological disease (237) and those without any malignant history (237). Demographic and hematologic analysis aim to unveil COVID-19 impact on individuals with cancer history. Results Statistically significant differences in blood parameters highlighted distinctions, with cancer patients exhibiting higher creatinine, leukocyte, and D Dimers levels as well as lower hemoglobin, neutrophile, lymphocyte, and Serum Glutamate-Pyruvate Transaminase (SGPT) levels. Non-significant differences in certain parameters prompted a nuanced exploration of metabolic and coagulation variations. Conclusion This study unveils global COVID-19 effects on cancer patients, emphasizing clinical and laboratory differences. Findings underscore the imperative need for targeted interventions and enhanced support for cancer patients during the pandemic. Study limitations stress careful interpretation, urging further exploration of COVID-19 and cancer interplay.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.